How Machine Learning is Improving Patient Outcomes: 5 Use Cases in 5 Minutes
by Mike Munsell, PhD
Director of Research, Panalgo
Thought Leadership
Check out Panalgo thought leadership articles to see our experts' takes on important topics in the healthcare analytics industry.
Emerging Topics in Real-World Evidence: Part 2
A Q&A with Dr. Samy Suissa
Emerging Topics in Real-World Evidence: Part 1
A Q&A with Dr. Peter Neumann, ScD
From Our Point of View: Highlights of DIA 2023
DIA 2023 was in Panalgo’s hometown of Boston last week and as usual, it did not disappoint. This year’s theme was ‘Illuminate’ – shining a light on many important topics such as diversity in clinical studies, artificial intelligence (AI), and personalized or precision medicine. Some newer concepts surfaced as well, including a provocative discussion of […]
How Life Sciences is Leveraging Machine Learning: 5 Use Cases in 5 Minutes
By Mike Munsell, PhD
Insights & Innovators: Is Lab Data the Secret Weapon for More Efficient Clinical Trials?
By Ritupriya Yamujala
How Machine Learning Can Advance Disease Predictability
By Chao Li, PhD, Data Scientist at AbbVie, and Mike Munsell, Director of Research at Panalgo
Insights & Innovators: Using Machine Learning to Develop Disease Predictability Models
Q&A with Chao Li, PhD
How Life Sciences Companies Can Strengthen Regulatory Submissions With External Control Arms
Applied Clinical Trials article from Panalgo's Executive Director of Solutions Engineering, Meg Richards, PhD.
How Stakeholders Can Maximize the Value of Real-World Data Analytics
Pharmacy Times article with Solutions Engineer Matthew Marshall on how payors can leverage RWD analytics.
Insights & Innovators: A Q&A with Greg Norman and Poorva Nemlekar from Dexcom
Q&A with Greg Norman and Poorva Nemlekar from Dexcom
Insights & Innovators: A Q&A with Greg Norman and Katia Hannah from Dexcom
Q&A with Greg Norman and Katia Hannah from Dexcom
A Game-Changing Shift: Why Pharma Commercial Teams Are Turning to HEOR
Chris Harvey and Carolyn Zele discuss the insights that health economics and outcomes research (HEOR) professionals bring to commercial teams. They explain how that pairing benefits both manufacturers and patients.
Building a Real-World Evidence Center of Excellence: Lessons from the Frontlines
Q&A with Margaret McDonald, Head of Apex Data Consulting, LLC, following a 17+ year career at Pfizer.
Transforming Healthcare Analytics with Machine Learning
Healthcare Business Today article from Zeynep Icten, PhD, Director of Data Science Solutions at Panalgo.
Using Machine Learning in the Evolving Landscape of Real-World Data
HIT Consultant article from Zeynep Icten, PhD, Director of Data Science Solutions at Panalgo.
RWE: Supporting Regulatory Submissions with Real-World Evidence
HIT Consultant article from Director of Analytics Solutions, Tiffany Siu Woodworth, MBA, MPH.
Leveraging RWD in Observational Studies: Understanding the Implications of Time-Related Biases
Q&A with Samy Suissa, PhD
Innovating RWE Organizations: Learning from the Past and Looking to the Future
Q&A with Christopher Boone, PhD, FACHE, FHIMMS
Tips to Improving Data Visualization in Healthcare
Article in Health IT Answers by Catherine Richards, PhD, MPH - Senior Vice President of Analytics and Scientific Engagement at Panalgo.
Operationalizing RWE Teams Across The Enterprise
Article in Life Science Leader by Catherine Richards, PhD, MPH - Senior Vice President of Analytics and Scientific Engagement at Panalgo.
How Real-World Data Can Help Us Better Prepare for the Next Pandemic
Scientific American article by Panalgo CEO, Joseph Menzin, PhD, and Panalgo Strategic Advisory Board member, Peter Neumann, ScD.
Pharma Commercial Teams: Building an Analytics Culture as a Driver of Competitive Advantage
By David Kreutter, PhD
Viewpoint: Life Sciences Should View Commercial Analytics Teams as a Revenue Generator
Q&A with Vijay Raghavan, Associate Vice President, Market Analytics and Business Insights, AbbVie
Interview with Dr. Mark Friedman on Covid-19 Complications and the Use of Real-World Data
Q&A with Dr. Mark Friedman
You Can Influence ICER Recommendations, You Just Need the Right Evidence
By Matthew Sussman, MA
5 Steps To Prepare For A Third-Party Drug Price Evaluation
Life Science Leader article from VP of Modeling & Evidence, Matt Sussman.
BHE is Now Panalgo: Why We Changed Our Name and Brand
By Joe Menzin, PhD
The Pressure To Publish Rapidly: The Risks Vs. Rewards Of Fast-Tracked COVID-19 Studies
Joseph Menzin, PhD, discusses the risks and rewards of fast-tracked COVID-19 studies.
Pandemic Pricing: The Risks and Rewards of Fast-Tracking Value-Based Drug Evaluations
Matthew Sussman, BHE's VP of Modeling & Strategy Services, discusses the use of remdesivir for COVID-19 patients and the risks and rewards of fast tracking value-based drug evaluations.
Gaining Rapid Understanding of COVID-19 Through a Real-world Data Lens
Healthcare IT Today article from Panalgo Founder and Executive Chairman, Joseph Menzin, PhD.
The Future of Healthcare: “We need to recognize that health outcomes are not just about medical care”, With Dr. Joseph Menzin of Boston Health Economics
Interview on the future of the healthcare industry with Joseph Menzin, PhD.
ICER’s Development and Use of RWE: 5 Areas for Concern
By Matthew Sussman, MA
Five Ways to Use Early-Stage Models to Support Your Drug’s Value Proposition
By Jennifer Benner
ICER Versus NICE: Who Cares About Value-Based Pricing Assessments?
By Matthew Sussman, MA
Do Fixed Cost-Effectiveness Thresholds or CE Threshold Magnitudes Matter?
By Matthew Sussman, MA
How Does ICER’s Incremental Cost-Effectiveness Analysis Stack Up to Industry Practice?
By Matthew Sussman, MA
IHD Analytics
Put reliable, rapid analytics in the hands of more people across your organization
